

Supplementary Data

Axl, Immune Checkpoint and HIF Inhibitors from Culture Broth of *Lepista luscina*

Mihaya Kotajima ^{1,†}, Jae-Hoon Choi ^{1,2,3,4,†}, Mitsuru Kondo ^{1,2}, Corina N. D'Alessandro-Gabazza ⁵, Masaaki Toda ⁵, Taro Yasuma ⁵, Esteban C. Gabazza ⁵, Yukihiro Miwa ⁶, Chiho Shoda ⁶, Deokho Lee ⁶, Ayaka Nakai ⁶, Toshihide Ku-rihara ⁶, Jing Wu ^{3,4}, Hirofumi Hirai ^{1,2,3,4} and Hirokazu Kawagishi ^{3,4,*}

¹ Graduate School of Science and Technology, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529, Japan

² Research Institute of Green Science and Technology, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529, Japan

³ Faculty of Agriculture, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529, Japan

⁴ Research Institute for Mushroom Science, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529, Japan

⁵ Department of Immunology, Mie University Graduate School of Medicine, Edobashi 2-174, Mie 524-8507, Japan

⁶ Department of Ophthalmology, Keio University School of Medicine, 35 Shina-nomachi, Shinjuku-ku, Tokyo 160-8582, Japan

* Correspondence: kawagishi.hirokazu@shizuoka.ac.jp

† These authors contributed equally to this work.




Figure S1. HPLC profile of metabolites from hexane soluble part of liquid culture of *L. luscina*.




Figure S2. ^1H NMR spectrum of **1** (CDCl_3).




Figure S3. ¹³C NMR spectrum of **1** (CDCl₃).




Figure S4. COSY spectrum of **1** (CDCl₃).




Figure S5. HMBC spectrum of **1** (CDCl₃).




Figure S6. HMQC spectrum of **1** (CDCl₃).




Figure S7. ORTEP drawings of **2** with ellipsoids at the 50% probability level.

Table S1. Crystallographic table of **2**.

Empirical formula	C ₁₅ H ₈ N ₂ O ₂
Formula weight	248.23
Temperature/K	173.15
Crystal system	monoclinic
Space group	<i>P</i> 2 ₁ / <i>n</i>
<i>a</i> /Å	7.3022 (2)
<i>b</i> /Å	7.5655 (2)
<i>c</i> /Å	19.4313 (5)
α /°	90
β /°	91.160 (2)
γ /°	90
Volume/Å ³	1073.26 (5)
<i>Z</i>	4
ρ_{calc} /g/cm ³	1.536
μ /mm ⁻¹	0.105
<i>F</i> (000)	512.0
Crystal size/mm ³	0.34 × 0.15 × 0.1
Radiation	Mo <i>K</i> α (λ = 0.71073)
Reflections collected	21807
Independent reflections	2908 [<i>R</i> _{int} = 0.0283, <i>R</i> _{sigma} = 0.0199]
Data/restraints/parameters	2908/0/204
Goodness-of-fit on <i>F</i> ²	1.063
Final <i>R</i> indexes [<i>I</i> > σ (<i>I</i>)]	<i>R</i> ₁ = 0.0464, <i>wR</i> ₂ = 0.1154
Final <i>R</i> indexes [all data]	<i>R</i> ₁ = 0.0551, <i>wR</i> ₂ = 0.1196
Largest diff. peak/hole / e Å ⁻³	0.45/-0.21

A suitable crystal was selected and on a Rigaku VariMax Saturn CCD (1.2 kW Mo rotating anode) at 173 K. The structure was solved with the SHELXT and refined with the SHELXL refinement package using Least Squares minimization^{48,49}. The structure analyzed was essentially the same with the paper previously reported⁵⁰.

48. Sheldrick, G. M. *SHELXT* - Integrated space-group and crystal-structure determination. *Acta Crystallographica Section A* **2015**, 71, 3-8, doi:10.1107/S2053273314026370.

-
49. Sheldrick, G. M. Crystal structure refinement with *SHELXL*. *Acta Crystallographica Section C* **2015**, 71, 3-8, doi:10.1107/S2053229614024218.
50. Fedeli, W.; Mazza, F. J. Crystal structure of tryptanthrin (indolo[2,1-*b*]quinazoline-6,12-dione). *Journal of the Chemical Society, Perkin Transactions 2* **1974**, 13, 1621-1623, doi:10.1039/P29740001621.